Radiation and immunotherapy for kidney cancer that has spread
Part of Cancer, Kidney & urinary, Women’s health & pregnancy clinical trials.
This trial tests whether adding a special type of radiation to your current immunotherapy can help shrink kidney cancer tumors that have stopped responding or are stable. The goal is to see if the radiation can boost the immune system's ability to fight cancer elsewhere in the body.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older with kidney cancer that has spread to other parts of the body.
- You are currently on an immunotherapy drug (called a checkpoint inhibitor) and your doctor has determined your cancer is either stable or has started growing again.
- You have at least two measurable tumors that can be seen on scans or exams (like CT or MRI).
- You are planning to receive a type of high-dose radiation to one of these tumors.
- You must be able to understand and sign a consent form, or have someone do it for you if you are physically unable.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of targeted radiation therapy with a restart of immunotherapy for people whose kidney cancer has grown after prior immunotherapy. It aims to see if radiation can help the immune system fight the cancer again.
This trial tests combining a precise type of radiation (SABR) with standard targeted therapy and immunotherapy drugs for kidney cancer that has come back or spread. The goal is to see if adding radiation improves outcomes.
This trial tests a combination of targeted therapy (axitinib) and immunotherapy (toripalimab) alongside stereotactic body radiation therapy (SBRT) for kidney cancer that has come back or spread. It may be an option if you have a limited number of metastatic tumors that can be treated with radiation.
This trial tests whether combining radiation therapy with two types of immunotherapy (checkpoint inhibitors and an injectable drug called IMSA101) can help control metastatic kidney cancer that is only growing in a few spots. The goal is to see if this approach can shrink tumors and keep them from growing further.
This trial compares standard systemic therapy (medication) alone versus systemic therapy plus targeted radiation to the cancer spots for people with kidney cancer that has spread to a limited number of places (up to 5 spots). It aims to see if adding radiation helps control the cancer better.
This trial tests whether giving a higher radiation dose to some tumors can help control kidney cancer that has spread to other parts of the body. It is for people who cannot have surgery to remove these tumors and are already receiving other treatments.
Hear when a new Renal Cell Cancer Metastatic trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.